Bristol-Myers Squibb Co (NYSE:BMY) – William Blair lowered their Q1 2018 earnings per share (EPS) estimates for Bristol-Myers Squibb in a research note issued on Monday. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will earn $0.73 per share for the quarter, down from their prior forecast of $0.75. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2018 earnings at $0.73 EPS, Q3 2018 earnings at $0.76 EPS, Q4 2018 earnings at $0.78 EPS and FY2018 earnings at $3.00 EPS.
BMY has been the topic of a number of other research reports. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price on the stock. in a research note on Friday, December 22nd. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $65.58.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share.
Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after purchasing an additional 333,685 shares during the last quarter. BlackRock Inc. lifted its position in Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after purchasing an additional 2,367,864 shares during the last quarter. Dodge & Cox lifted its position in Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after purchasing an additional 459,271 shares during the last quarter. Jennison Associates LLC lifted its position in Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after purchasing an additional 910,496 shares during the last quarter. Institutional investors own 69.70% of the company’s stock.
In related news, Director Theodore R. Samuels II acquired 4,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by company insiders.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were issued a dividend of $0.40 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 271.19%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.